Dear Panel Members,

On behalf of Bristol-Myers Squibb Company, I respectfully submit the enclosed Opdivo® (nivolumab) clinical data that was presented at the 2019 European Society for Medical Oncology (ESMO) Annual Congress¹ and simultaneous manuscript, which was published in *Lancet Oncology* on September 30, 2019,² to the NCCN Esophageal and Esophagogastric Junction Cancers Panel for your consideration.

**ATTRACTION-3 (ONO-24 / CheckMate 473)** is a phase 3, multicenter, randomized, open-label study, which evaluated the use of nivolumab monotherapy for the second-line treatment of patients with unresectable advanced or recurrent esophageal squamous cell carcinoma (ESCC) refractory or intolerant to one prior fluoropyrimidine/platinum-based therapy. Patients received either nivolumab monotherapy or investigator’s choice of chemotherapy (docetaxel or paclitaxel) until disease progression or unacceptable toxicity.¹²

The use of nivolumab for the treatment of esophageal squamous cell carcinoma is considered investigational.³

**Rationale:** These data are being submitted in response to a standing request from NCCN for new data.

As part of this submission, the following resources are included for your review:


Thank you for your consideration of this request.

Sincerely,

Awny Farajallah, MD, FACP
Vice President, Head US Medical
Bristol-Myers Squibb Company